CLINICAL-TRIALS IN POST-MARKETING SURVEILLANCE OF DRUGS

被引：6

作者：

BELL, RL ^{[1
]}

SMITH, EO ^{[1
]}

机构：

[1] BAYLOR COLL MED,USDA,ARS,CNRC,DEPT PEDIAT,HOUSTON,TX 77030

来源：

CONTROLLED CLINICAL TRIALS | 1982年 / 3卷 / 01期

关键词：

D O I：

10.1016/0197-2456(82)90019-8

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

收藏

页码：61 / 68

页数：8

相关论文

共 14 条

[1] BLACKWELL B, 1975, CLIN PHARMACOL THER, V18, P653
[2] CROUT JR, 1975, CLIN PHARMACOL THER, V18, P634
[3] DOLLERY CT, 1976, CIBA F SYMP, V44, P73
[4] Inman WHW, 1978, EPIDEMIOLOGICAL ISSU, P17
[5] KLIMT CR, 1977, EPIDEMIOLOGIC EVALUA, P99
[6] REMINGTON RD, 1978, AM J PHARM, V150, P72
[7] REMINGTON RD, 1976, ASSESSING DRUG REACT, V7, P141
[8] DRUG EVALUATION AFTER MARKETING
SLONE, D
SHAPIRO, S
MIETTINEN, OS
FINKLE, WD
STOLLEY, PD
[J]. ANNALS OF INTERNAL MEDICINE, 1979, 90 (02) : 257 - 261
[9] POST-MARKETING SURVEILLANCE OF NEW DRUGS .1. REVIEW OF OBJECTIVES AND METHODOLOGY
WARDELL, WM
TSIANCO, MC
ANAVEKAR, SN
DAVIS, HT
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 19 (2-3) : 85 - 94
[10] WARDELL WM, 1977, DRUG MONITORING, P241